Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Ascendis Pharma A/S (ASND) had Normalized Income after Taxes of $-44.11M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$179.41M |
|
$-44.11M |
|
$35.70M |
|
$143.71M |
|
$239.52M |
|
$-60.11M |
|
$20.37M |
|
$-39.74M |
|
$-39.74M |
|
$-44.11M |
|
$-44.11M |
|
$-44.11M |
|
|
Normalized Income after Taxes |
$-44.11M |
$-60.11M |
|
$-54.85M |
|
60.45M |
|
63.91M |
|
$-0.73 |
|
$-0.93 |
|
| Balance Sheet Financials | |
$1.08B |
|
$106.19M |
|
$153.19M |
|
$1.23B |
|
$1.06B |
|
$374.83M |
|
$386.51M |
|
$1.45B |
|
$-212.93M |
|
$-217.23M |
|
$-212.93M |
|
60.55M |
|
| Cash Flow Statement Financials | |
$-24.58M |
|
$-5.72M |
|
$-12.54M |
|
$635.19M |
|
$560.84M |
|
$-74.35M |
|
$63.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.02 |
|
-- |
|
-- |
|
2.32 |
|
-4.23 |
|
80.10% |
|
-33.50% |
|
-33.50% |
|
-- |
|
-22.15% |
|
-24.58% |
|
$-30.30M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
0.10 |
|
1.30 |
|
69.03 |
|
20.71% |
|
20.30% |
|
-3.57% |
|
-27.24% |
|
$-3.52 |
|
$-0.47 |
|
$-0.38 |
|